{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16.7"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"16.7"},{"groupId":"OG007","value":"33.3"},{"groupId":"OG008","value":"16.7"},{"groupId":"OG009","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"}],"units":"Participants"}],"description":"Percentage of participants with at least one dose reduction were reported.","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 twice daily (BID) as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"NUMBER","populationDescription":"The safety set included all participants who had received at least one dose of LTT462.","reportingStatus":"POSTED","timeFrame":"Up to 2.8 years","title":"Percentage of Participants With at Least One Dose Reduction","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}